Fintel reports that on December 16, 2024, Stifel upgraded their outlook for Denali Therapeutics (NasdaqGS:DNLI) from Hold to ...

Shares of Denali Therapeutics Inc. (NASDAQ:DNLI – Get Free Report) have received a consensus recommendation of “Moderate Buy” ...

Stifel upgraded Denali Therapeutics (DNLI) to Buy from Hold with a $37 price target Denali recently aligned with the FDA to file for ...

Check the time stamp on this data. Updated AI-Generated Signals for Denali Therapeutics Inc. (DNLI) available here: DNLI.

Denali Therapeutics (DNLI) announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug leucine-rich ...

Denali Therapeutics (NASDAQ:DNLI) Inc. shares soared to a 52-week high, reaching a price level of $25.25. The biotechnology firm, which specializes in developing ...

Denali Therapeutics (DNLI) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

SOUTH SAN FRANCISCO, Calif., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Denali Therapeutics Inc. (Nasdaq: DNLI) today reported financial results for the third quarter ended September 30, 2024, and provided ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...